- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03119610
The Physiologic Effects of Intranasal Oxytocin on Sarcopenic Obesity (INOSO)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The pilot study will be conducted at 3 sites in 9 visits over a period of 12+ weeks. Older sedentary subjects will be screened for sarcopenic obesity using a modified consensus definition and evaluated at baseline for safety labs, glucose tolerance, body composition, cognition and physical performance, as well as systemic inflammatory markers in blood and muscle tissue.
Eligible subjects self-administer 24 IU intranasal oxytocin four times a day for 8 weeks.
The study will examine whether the intervention will promote weight loss and preserve muscle mass, thereby preserving and/or improving physical function in older subjects with sarcopenic obesity.
Generalized linear mixed effects model will be used to evaluate the effect of oxytocin on the change of each continuous measure. The effect of oxytocin will be assessed by whether the time by oxytocin interaction is significantly different from 0 with a 2-sided p-value<0.05.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Texas
-
San Antonio, Texas, United States, 78207
- Texas Diabetic Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- BMI 30-40 kg/m2
- Sedentary (< 2 strenuous exercise/week)
- Gait speed < 1 meter/second
Exclusion Criteria:
- Diabetes (ADA criteria)
- Heart disease (MI or New York Heart Classification grade III-IV)
- Poorly controlled hypertension (SBP > 170 or DBP >95 mm/Hg)
- Anemia (Hematocrit <34%)
- Renal Disease (Serum Creatinine >1.4, abnormal serum sodium levels, abnormal urinalysis, or physical exam findings indicative of fluid imbalance; individuals with underlying disorder of sodium/water balance, such as SIADH, diabetes insipidus, or psychogenic polydipsia)
- Liver Disease (AST/ALT/AlkPhos > 2x upper limit of normal)
- Use of systemic steroid, androgens, or anti-coagulants
- Active/unstable conditions: inflammatory, thyroid, autoimmune, gastrointestinal (GI), hematologic, or neoplastic disorders
- Individuals with underlying seizure disorder or underlying neurologic disorder that increases seizure risk
- Cognitive impairment (MiniCog <3), unstable mental illness, substance abuse, or history of eating disorder
Study Plan
How is the study designed?
Design Details
- Primary Purpose: BASIC_SCIENCE
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Oxytocin nasal spray
Oxytocin (Syntocinon), intranasal, 24IU, 4x a day for 8 weeks, self administered
|
Self administered Oxytocin nasal spray q.i.d. for 8 weeks versus placebo (normal saline nasal spray)
Other Names:
|
EXPERIMENTAL: Placebo nasal spray
Placebo nasal spray, 4x a day for 8 weeks, self administered
|
Self administered Placebo nasal spray q.i.d. for 8 weeks (normal saline nasal spray)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Body Weight
Time Frame: Baseline to 8 weeks
|
Intranasal oxytocin will promote weight loss and preserve muscle mass
|
Baseline to 8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Fat Mass
Time Frame: Baseline to 8 weeks
|
Pre- and post-measurements of fat mass by dual energy x-ray absorptiometry (DXA) will be examined for individual change with intranasal oxytocin
|
Baseline to 8 weeks
|
Change in Body Mass Index
Time Frame: 8 weeks
|
Pre- and post-measurements of lean mass by DXA will be examined for individual change with intranasal oxytocin.
Change in body mass index (BMI).
|
8 weeks
|
Change in Glucose Levels Measured Using the Glucose Tolerance Test
Time Frame: 8 weeks
|
Pre- and post-measurements of oral glucose tolerance test for 2-hour plasma glucose will be examined for individual change with intranasal oxytocin
|
8 weeks
|
Change in Short Physical Performance Battery (SPPB)
Time Frame: Baseline to 8 weeks
|
Pre- and post-measurements will be examined for individual change with intranasal oxytocin. This battery of tests is scored on a scale with 3 SPPB calculation components:
Total Score is the sum of all 3 scores: Minimum = 0 Maximum = 12. Higher scores indicate better lower extremity function. Difference between baseline and 8 week performance is reported. |
Baseline to 8 weeks
|
Change in HbA1c (Hemoglobin A1c)
Time Frame: Baseline to 8 weeks
|
Pre- and post-measurements will be examined for individual change with intranasal oxytocin
|
Baseline to 8 weeks
|
Change in Waist Circumference
Time Frame: Baseline to 8 weeks
|
Pre- and post-measurements will be examined for individual change with intranasal oxytocin
|
Baseline to 8 weeks
|
Change in Total Cholesterol
Time Frame: Baseline to 8 weeks
|
Pre- and post-measurements will be examined for individual change with intranasal oxytocin
|
Baseline to 8 weeks
|
Change in Low Density Lipoproteins (LDL)
Time Frame: Baseline to 8 weeks
|
Pre- and post-measurements will be examined for individual change with intranasal oxytocin
|
Baseline to 8 weeks
|
Change in High Density Lipoproteins (HDL)
Time Frame: Baseline to 8 weeks
|
Pre- and post-measurements will be examined for individual change with intranasal oxytocin
|
Baseline to 8 weeks
|
Change in Triglycerides
Time Frame: Baseline to 8 weeks
|
Pre- and post-measurements will be examined for individual change with intranasal oxytocin
|
Baseline to 8 weeks
|
Change in Center for Epidemiologic Studies Scale (CES-D)
Time Frame: Baseline to 8 weeks
|
Pre- and post-measurements will be examined for individual change with intranasal oxytocin. This is measured on a 20 item scale using the following scoring using number of week days:
|
Baseline to 8 weeks
|
Change in Montreal Cognitive Assessment (MoCA)
Time Frame: Baseline to 8 weeks
|
Pre- and post-measurements will be examined for individual change with intranasal oxytocin.
A 30-point test, with a score of 0 or 1 assigned to each item.
The minimum score is 0 and the maximum is 30.
The higher the score, the less cognitive impairment.
|
Baseline to 8 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Sara Espinoza, MD, The University of Texas Health Science Center, San Antonio
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HSC20160661H
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obesity
-
Central Hospital, Nancy, FranceNot yet recruiting
-
University of MinnesotaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Active, not recruitingAdolescent ObesityUnited States
-
Helsinki University Central HospitalKarolinska Institutet; Folkhälsan Researech CenterEnrolling by invitation
-
Istanbul Medipol University HospitalMedipol UniversityCompletedObesity, Morbid | Obesity, Adolescent | Obesity, Abdominal | Weight, Body | Obesity, VisceralTurkey
-
Queen Fabiola Children's University HospitalNot yet recruitingMorbid Obesity | Adolescent Obesity | Bariatric SurgeryBelgium
-
Azienda Ospedaliero-Universitaria Consorziale Policlinico...Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies; Istituti... and other collaboratorsCompletedMorbid Obesity | Metabolically Healthy ObesityItaly
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; Pennington Biomedical Research... and other collaboratorsActive, not recruitingOvernutrition | Nutrition Disorders | Overweight | Body Weight | Pediatric Obesity | Body Weight Changes | Childhood Obesity | Weight Gain | Adolescent Obesity | Obesity, Childhood | Overweight and Obesity | Overweight or Obesity | Overweight AdolescentsUnited States
-
The Hospital for Sick ChildrenCompleted
-
Ihuoma EneliCompletedObesity, ChildhoodUnited States
-
Fundació Sant Joan de DéuRecruitingObesity, Childhood | Obesity, AdolescentSpain
Clinical Trials on Oxytocin nasal spray
-
University Hospital, ToulouseCompletedPrader-Willi SyndromeFrance
-
University of Electronic Science and Technology...Completed
-
Massachusetts General HospitalCompleted
-
University of Sao Paulo General HospitalTerminated
-
Florida Institute for Human and Machine CognitionUniversity of Alabama at Birmingham; University of Florida; Translational Genomics... and other collaboratorsCompleted
-
Rambam Health Care CampusCompletedPost Traumatic Stress DisorderIsrael
-
Florida Institute for Human and Machine CognitionUniversity of Florida; Office of Naval Research (ONR)Completed
-
University of North Carolina, Chapel HillCompletedSchizophrenia | Schizoaffective Disorder | ParanoiaUnited States
-
Stanford UniversityCompleted
-
King's College LondonFather Flanagan's Boys' HomeCompletedAntisocial Personality DisorderUnited Kingdom